EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong

HONG KONG, Oct 3, 2022 – (ACN Newswire) – EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group and the Seller enters into a sale and purchase agreement to acquire 60% of the issued share capital of Pioneer Evolution Limited (the "Target Company") for a total consideration of HK$36.4 million in cash. The Target Company is a controlling holding company of a medical service provider which has a long-standing history in providing multi-disciplinary healthcare services … Continue reading EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong

Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

BANDUNG, INDONESIA, Oct 2, 2022 – (ACN Newswire) – PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23. Under the contract, Bio Farma will export its oral polio vaccines based on purchase requests from UNICEF via multilateral contract agreement for the years 2022 & 23. Indonesian State-Owned Enterprises (SOEs) Minister Erick Thohir has said, "In line with the theme of the Indonesian G20 Presidency, "Recover Together, Recover Stronger", it is important … Continue reading Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

Q&M Group awards 7 dentists with Performance Shares,12-year Service Agreements, and a Private Placement

SINGAPORE, Sep 30, 2022 – (ACN Newswire) – Mainboard-listed Q&M Dental Group (Singapore) Limited [SGX: QC7] announced on 29 September 2022 the award of 2,014,245 shares to 7 promising next-generation dentists as part of the Q&M Performance Share Plan (PSP) 2018, as well as the proposed placement of an additional 4,985,755 treasury shares, totalling S$1.75 million, through placement to the same dentists.These 7 Key Dentists are the recipients of awards under the PSP 2018 by Q&M in its announcement dated 29 September 2022. These Key Dentists have also expressed their interest to subscribe for further shares as an expression of … Continue reading Q&M Group awards 7 dentists with Performance Shares,12-year Service Agreements, and a Private Placement

My Platform Joint Venture Awarded the Winner’s Prize in the 2022 Hong Kong-Macau-Taiwan Innovation and Entrepreneurship Competition

HONG KONG, Sep 29, 2022 – (ACN Newswire) – My Platform, the MedTech venture in which Black Spade Capital Limited ("Black Spade Capital") invested, has just announced that its PRC joint venture My Platform Information Technology (Guangzhou) Limited ("My Platform MedTech") was awarded the Winner's Prize in the 2022 Hong Kong-Macau-Taiwan Innovation and Entrepreneurship Competition organised by the Guangzhou Municipal Science and Technology Bureau. (1st from the Right) Mr. Jesse Ho, Chief Executive Officer of My Platform The competition brings together 226 participants from a wide variety of industries to honour the key players from Hong Kong, Macau and Taiwan … Continue reading My Platform Joint Venture Awarded the Winner’s Prize in the 2022 Hong Kong-Macau-Taiwan Innovation and Entrepreneurship Competition

Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

HONG KONG, Sep 28, 2022 – (ACN Newswire) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that interim safety and efficacy data of dose expansion cohort from the phase I/II study of TST001 (Osemitamab), a humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, in combination with Capecitabine and Oxaliplatin (CAPOX) as a first line treatment of locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer was presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2022. In first line treatment of advanced or … Continue reading Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

Avance Clinical Wins International Health Award for Biotech CRO Services

SYDNEY, AU, Sep 28, 2022 – (ACN Newswire) – Avance Clinical, the leading Australian-based biotech CRO with US operations has won the South Australian Premier's Export Awards – International Health category. The award recognises excellence in clinical services exports. Avance Clinical CEO Yvonne Lungershausen The Premier of South Australia Peter Malinauskas, and Minister for Trade and Investment Nick Champion, presented the Premier's Export Awards to Avance Clinical CEO Yvonne Lungershausen at the awards industry event today. This follows Avance Clinical's selection as finalist for the Informa Pharma Intelligence Awards 2022 Best Contract Research Organization in APAC. Avance Clinical, which is … Continue reading Avance Clinical Wins International Health Award for Biotech CRO Services

Corinium presents: Data & Analytics in Healthcare Online ASEAN

Singapore, Sep 28, 2022 – (ACN Newswire) – Join Corinium's Data and Analytics in Healthcare ASEAN on October 18 and learn how healthcare can use data and analytics to revolutionise patient experience. Attracting everyone from hospitals to government, insurers to community health, you will hear how the leading minds in healthcare are making actionable insights from their huge data sets. Through a range of cutting-edge case studies and presentations, issues tackled will include data governance, data-driven decision-making, predictive analytics, data integration and automation, patient turnaround improvement, digital transformation implementation in healthcare, and data-centric culture embedding. Join this sensational line up … Continue reading Corinium presents: Data & Analytics in Healthcare Online ASEAN

HMA conference to look at future of Hospital at Home model in Asia

Singapore, Sep 28, 2022 – (ACN Newswire) – With limited hospital capacity and growing demand for care, Hospital at Home (HaH) programmes have gained traction over the world as an alternative care delivery model. Scaling up HaH is a complex affair though. Various stakeholders have to be involved and engaged – besides patients and clinicians, there are the caregivers, third-party payers and policymakers and solutions providers – to ensure tertiary hospital care can be delivered seamlessly into a patient's home, with the best outcomes and care experience.This is why Hospital Management Asia is organising the Hospital@Home Asia conference, with Singapore's … Continue reading HMA conference to look at future of Hospital at Home model in Asia

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

HONG KONG, Sep 23, 2022 – (ACN Newswire) – AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), announced the proposed listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.AIM Vaccine plans to offer an aggregate of 9,714,000 H shares (the "Offer Shares") under the Global Offering (subject to the Over-allotment Option), comprising an international offering (the "International Offering") of 8,742,400 H shares … Continue reading AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Mediwelcome Announced 2022 Interim Results

HONG KONG, Sep 23, 2022 – (ACN Newswire) – A China's leading provider of digital medical service solutions – Mediwelcome Healthcare Management & Technology Inc. ("Mediwelcome" or the "Company", and together with its subsidiaries, the "Group") (Stock Code: 2159), announced the unaudited consolidated interim results for the six months ended 30 June 2022 (the "Reporting Period" or the "First half of 2022"). In the first half of 2022, Mediwelcome has narrowed in revenue and other aspects to varying degrees due to the continuous lockdown in many provinces in response to the severe pandemic in the PRC. In the first half … Continue reading Mediwelcome Announced 2022 Interim Results